Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
- HealthCare Royalty and Heidelberg Pharma amend royalty financing agreement to provide for USD 20 million payment
- Heidelberg Pharma extends cash runway into 2027
Ladenburg, Germany, 13 March 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed an amendment to the royalty financing agreement entered into in March 2024.
